| P50 | author | Rolf Hilgenfeld | Q28039171 |
| | Johan Neyts | Q29460378 |
| | Pieter Leyssen | Q29460394 |
| | Mathy Froeyen | Q114401432 |
| | Aloys Tijsma | Q114401435 |
| P2093 | author name string | Simon Tucker | |
| | David Franco | |
| P2860 | cites work | Activity of pleconaril against enteroviruses | Q24550640 |
| | Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes | Q27619756 |
| | 3C Protease of Enterovirus 68: Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against Picornaviruses | Q27676219 |
| | More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules | Q27681644 |
| | Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials | Q28178690 |
| | In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity | Q28343180 |
| | In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses | Q30306034 |
| | Treatment of potentially life-threatening enterovirus infections with pleconaril | Q31918011 |
| | Hand, foot, and mouth disease in China, 2008-12: an epidemiological study | Q33668897 |
| | Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q34347924 |
| | Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication | Q36387676 |
| | Potential use of antiviral agents in polio eradication | Q36944919 |
| | In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection | Q39412134 |
| | Towards the design of combination therapy for the treatment of enterovirus infections | Q39564162 |
| | In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors | Q39742772 |
| | An inactivated enterovirus 71 vaccine in healthy children | Q40216677 |
| | Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment | Q40375873 |
| | Enterovirus 71 meningoencephalitis during chemotherapy in a child with metastatic osteosarcoma | Q40440541 |
| | Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors | Q40740581 |
| | Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China | Q42226974 |
| | The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways | Q42524022 |
| | An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus | Q43617763 |
| | Inhibition of Rhinovirus Replication in Organ Culture by a Potential Antiviral Drug | Q44124666 |
| | Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis | Q44400134 |
| | Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility. | Q54132214 |
| | Anti-enterovirus activity and structure–activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles | Q56786343 |
| | Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease | Q73198212 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6990-6992 | |
| P577 | publication date | 2014-09-08 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication | |
| P478 | volume | 58 | |